Effects of Rhomboid Intercostal Block on Postoperative Pain Management and Chronic Pain Incidence in Mastectomies
CompletedNot applicableNCT06756048
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this clinical trial is to evaluate the effects of the Rhomboid Intercostal Block (RIB) on postoperative chronic pain prevalence at 3 months (primary outcome) and on acute pain control, total opioid consumption, and the incidence of opioid-related side effects within the first 24 hours (secondary outcomes) in patients undergoing elective mastectomy surgery. The main questions it aims to answer are: Does the application of RIB reduce the prevalence of chronic pain at 3 months postoperatively? Does RIB improve acute pain control and reduce opioid consumption and related side effects in the first 24 hours postoperatively? Researchers will compare patients who receive RIB under general anesthesia to those who do not receive the block to determine its effectiveness in reducing chronic pain prevalence, acute pain scores, and opioid-related outcomes.
Study details
- Official title
- Study of the Effects of Rhomboid Intercostal Block on Acute Postoperative Pain Management and Chronic Pain Incidence in Patients Undergoing Oncologic Breast Surgery
- Conditions
- Mastectomy
- Rhomboid Intercostal Block
- Chronic Pain Following Surgical Procedure for Cancer
- Interventions
- Procedure: Rhomboid Intercostal Nerve Block
- Sponsor
- Koç University
- Start date
- 2023-11-27
- Primary completion
- 2024-11-27
- Sex
- Female
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients undergoing one of the following procedures: benign mass excisions, modified radical mastectomies (MRM), simple total mastectomies, nipple-sparing mastectomies, or skin-sparing mastectomies, regardless of additional procedures such as sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or implant placement. Exclusion Criteria: * Patients undergoing breast augmentation, reduction, or mammoplasty without a mass. * Patients with a BMI \> 35. * Emergency cases. * Patients with bleeding diathesis. * Known allergy to medications used in the study. * Patients with asthma. * Patients diagnosed with chronic kidney failure. * Pregnant or lactating patients. * Patients with chronic opioid use. * Patients with cooperation issues or inadequate communication ability. * Male patients.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06756048